{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:42:34Z","timestamp":1773772954546,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100017551","name":"Children\u2019s National Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Based on clinical outcomes in colorectal cancer, high microsatellite instability (MSI-H) has recently been approved by the Food and Drug Administration (FDA) as a genetic test to select patients for immunotherapy targeting PD-1 and\/or CTLA-4 without limitation to cancer type. However, it is unclear whether the MSI-H would broadly alter the tumor microenvironment to confer the therapeutic response of different cancer types to immunotherapy. To fill in this gap, we performed an in silico analysis of tumor immunity among different MSI statuses in five cancer types. We found that consistent with clinical responses to immunotherapy, MSI-H and non-MSI-H samples from colorectal cancer (COAD-READ) exhibited distinct infiltration levels and immune phenotypes. Surprisingly, the immunological difference between MSI-H and non-MSI-H samples was diminished in stomach adenocarcinoma and esophageal carcinoma (STAD-ESCA) and completely disappeared in uterine corpus endometrial carcinoma (UCEC). Regardless of cancer types, the abundance of tumor-infiltrating immune cells, rather than MSI status, strongly associated with the clinical outcome. Since preexisting antitumor immune response in the tumor (hot cancer) is accepted as a prerequisite to the therapeutic response to anti-PD-1\/CTLA-4 immunotherapy, our data demonstrate that the impact of MSI varied on immune contexture will lead to the further evaluation of predictive immunotherapy responsiveness based on the universal biomarker of MSI status.<\/jats:p>","DOI":"10.1093\/bib\/bbaa180","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T19:07:29Z","timestamp":1594753649000},"source":"Crossref","is-referenced-by-count":33,"title":["Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers"],"prefix":"10.1093","volume":"22","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Immunotherapy and the Director of Bioinformatics Core at the Institute of Human Virology, University of Maryland School of Medicine, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0928","authenticated-orcid":false,"given":"Ya","family":"Cui","sequence":"additional","affiliation":[{"name":"University of Chinese Academy of Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, MD, USA and OncoImmune, Inc. Rockville, MD 20852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, MD, USA and OncoImmune, Inc. Rockville, MD 20852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,22]]},"reference":[{"key":"2021052110393698300_ref1","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J","article-title":"Microsatellite instability in human solid tumors","volume":"82","author":"Arzimanoglou","year":"1998","journal-title":"Cancer"},{"key":"2021052110393698300_ref2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-14-1397","article-title":"The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy","volume":"5","author":"Xiao","year":"2015","journal-title":"Cancer Discov"},{"key":"2021052110393698300_ref3","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat Commun"},{"key":"2021052110393698300_ref4","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2021052110393698300_ref5","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052110393698300_ref6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Luber","year":"2017","journal-title":"Science (80-)"},{"key":"2021052110393698300_ref7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site \u2014 when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"2021052110393698300_ref8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrclinonc.2017.132","article-title":"Nivolumab effective against MSI tumours","volume":"14","author":"Cancer","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2021052110393698300_ref9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021052110393698300_ref10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021052110393698300_ref11","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell\u2013inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"2021052110393698300_ref12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13073-017-0434-0","article-title":"Multilevel genomics of colorectal cancers with microsatellite instability\u2014clinical impact of JAK1 mutations and consensus molecular subtype 1","volume":"9","author":"Sveen","year":"2017","journal-title":"Genome Med"},{"key":"2021052110393698300_ref13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature14173","article-title":"Differential DNA mismatch repair underlies mutation rate variation across the human genome","volume":"521","author":"Supek","year":"2015","journal-title":"Nature"},{"key":"2021052110393698300_ref14","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"2021052110393698300_ref15","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"2021052110393698300_ref16","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"2021052110393698300_ref17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"2021052110393698300_ref18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021052110393698300_ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2021052110393698300_ref20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2021052110393698300_ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01473","article-title":"MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"2021052110393698300_ref22","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2021052110393698300_ref23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356144","article-title":"Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients","volume":"7","author":"Xing","year":"2018","journal-title":"Oncoimmunology"},{"key":"2021052110393698300_ref24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw027","article-title":"Tumor-infiltrating lymphocytes, Crohn\u2019s-like lymphoid reaction, and survival from colorectal cancer","volume":"108","author":"Rozek","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021052110393698300_ref25","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa180\/37965318\/bbaa180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa180\/37965318\/bbaa180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T10:40:44Z","timestamp":1621593644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaa180\/5895437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa180","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2020,8,22]]},"article-number":"bbaa180"}}